General
Preferred name
GLICLAZIDE
Synonyms
S1702 ()
SE1702 ()
S1702, SE1702 ()
Gliclazida ()
S-1702 ()
Zicron ()
Vitile XL ()
Diaglyk ()
J3.151H ()
Vamju ()
Diamicron ()
Edicil ()
SE 1702 ()
Ziclaseg ()
Diamicron MR ()
Bilxona ()
Zicron PR ()
Nazdol MR ()
S-852 ()
NSC-758673 ()
Glimicron ()
Glimil ()
SE-1702 ()
Dacadis MR ()
P&D ID
PD001261
CAS
21187-98-4
Tags
available
drug
First approval
1972
Drug indication
diabetes mellitus
Diabetic complication
Drug Status
approved
investigational
Max Phase
3.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Gliclazide (S1702) is a whole-cell beta-cell ATP-sensitive potassium currents blocker with an IC50 of 184 nM. Gliclazide is used as an antidiabetic[1].
PRICE
29
DESCRIPTION
Gliclazide is a whole-cell beta-cell ATP-sensitive potassium currents blocker. It is used to treat hyperglycemia in patients with type 2 diabetes mellitus.
(Enamine Bioactive Compounds)
DESCRIPTION
Gliclazide (SE1702), an oral antihyperglycemic agent, belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating beta-cells of the pancreas to release insulin.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
16
Cayman Chemical Bioactives
ChEMBL Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine Bioactive Compounds
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
30
Molecular Weight
323.13
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
2
Rotatable Bonds
3
Ring Count
3
Aromatic Ring Count
1
cLogP
1.63
TPSA
78.51
Fraction CSP3
0.53
Chiral centers
2.0
Largest ring
6.0
QED
0.89
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Potassium Channel
Member status
member
MOA
K(ATP) Channel Blockers
Therapeutic Class
Hypoglycemic Agents
Pathway
Membrane Transporter/Ion Channel
Source data
